Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris

Clinical and Experimental Dermatology

Volumn 30, Issue 3, 2005, Pages 215-220

  Kus, S ^a   Yucelten, D ^b   Aytug, A ^b  

^a ACIBADEM HOSPITAL   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DOXYCYCLINE;

ACNE VULGARIS; ADULT; ANGIONEUROTIC EDEMA; ANTIBIOTIC THERAPY; ARTICLE; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; ERYTHEMA MULTIFORME; FEMALE; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HUMAN; INTRACRANIAL HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM SICKNESS; SIDE EFFECT; SINGLE BLIND PROCEDURE; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; VAGINITIS; VERTIGO;

ACNE VULGARIS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DOXYCYCLINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 17444365782     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2005.01769.x     Document Type: Article

References (23)

1. Pochi PE. The pathogenesis and treatment of acne. Annu Rev Med 1990; 41: 187-98.
2. Layton AM. Optimal management of acne to prevent scarring and psychological sequelae. Am J Clin Dermatol 2001; 2: 135-41.
3. Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its anti microbial, pharmacokinetic properties, and clinical efficacy. Drugs 1992; 44: 750-99.
4. Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol 1997; 36: 234-40.
5. Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol 2000; 39: 45-50.
6. Gruber F, Grubisic-Greblo H, Kastelan M. Azithromycin compared with minocycline in the treatment of acne comedonica and papulo-pustulosa. J Chemother 1998; 10: 469-73.
7. Harper JC. An update on the pathogenesis and management of acne vulgaris. J Am Acad Dermatol 2004; 51: S36-8.
8. Hopkins S. Clinical toleration and safety of azythromycin. Am J Med 1991; 91: 40S-5S.
9. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440-7.
10. Cunliffe WJ, Simpson NB. Disorders of the Sebaceous Glands in Textbook of Dermatology, Oxford: Blackwell Science, 1998: 1927-84.
11. Scheinfeld NS, Tutrone WD, Torres O, Weinberg JM. Macrolides in dermatology. Clin Derm 2003; 21: 40-9.
12. Alvarez-Elroco S, Enzler MJ. The macrolides, erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 1999; 74: 613-34.
13. Parsad D, Pandhi R, Nagpal R, Negi KS. Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. J Dermatol 2001; 28: 1-4.
14. Webster GF. Inflammation in acne vulgaris. J Am Acad Dermatol 1995; 33: 247-53.
15. Chalker DK, Shalita A, Smith JG, Swann RW. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983; 9: 933-6.
16. Skidmore R, Kovach R, Walker C et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139: 459-64.
17. Lavker RM, Leyden JJ, McGingley KJ. The relationship between bacteria and the abnormal follicular keratinization in acne vulgaris. J Invest Dermatol 1981; 77: 325-30.
18. Eady EA, Jones CE, Tipper JL et al. Antibiotic-resistant propionibacteria in acne: need for policies to modify antibiotic usage. Br Med J 1993; 306: 555-6.
19. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin-resistant propionibacteria in antibiotic-treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 51-7.
20. Oncu S, Punar M, Eraksoy H. Comparative activities of beta-lactam antibiotics and quinolones for invasive Streptococcus pneumoniae isolates. Chemotherapy 2004; 50: 98-100.
21. Jacobs MR, Bajaksouzian S, Windau A et al. Susceptibility of Streptococcus pneumoniae, Haemophilus influenza, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 US Surveillance Study. Clin Laboratory Med 2004; 24: 503-30.
22. Eady EA. Bacterial resistance in acne. Dermatology 1998; 196: 59-66.
23. Garner S, Eady A, Avery T. Robust evidence is needed in treating acne. Br Med J 2002; 325: 1422.